Results 1 to 10 of about 47,659 (253)
New Avenues for Phosphodiesterase Inhibitors in Asthma [PDF]
Journal of Experimental Pharmacology, 2021 Maria Gabriella Matera,1 Josuel Ora,2 Francesco Cavalli,2 Paola Rogliani,2,3 Mario Cazzola3 1Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Respiratory Diseases Unit, “Tor Vergata&rdquo ...
Matera MG +4 more
doaj +4 more sources
The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review
Frontiers in Pharmacology, 2022 Phosphodiesterase-1 (PDE1) is a versatile enzyme that has surprisingly received considerable attention as a possible therapeutic target in Alzheimer’s disease (AD) because it maintains the homeostasis of 3ʹ,5ʹ-cyclic adenosine monophosphate (cAMP) and 3ʹ,
Nazir Ahmad +5 more
doaj +1 more source
Phosphodiesterase Inhibitors: Present and Future
Barcelona Respiratory Network Reviews, 2023 Phosphodiesterase (PDE) inhibitors act on specific phosphodiesterase enzymes (fundamentally 3, 4 and 5), which are characterized by their expression in different organs.
José L. Izquierdo-Alonso
doaj +1 more source
Phosphodiesterase inhibitors [PDF]
British Journal of Pharmacology, 2006 Phosphodiesterases are a diverse family of enzymes that hydrolyse cyclic nucleotides and thus play a key role in regulating intracellular levels of the second messengers cAMP and cGMP, and hence cell function. Theophylline and papaverine have historically been used therapeutically and are known to be weak inhibitors of PDE, but to what extent this ...
Boswell-Smith, V, Spina, D, Page, C P
openaire +3 more sources
Applied Sciences, 2021 Alzheimer’s disease is a memory-related neurodegenerative condition leading to cognitive impairment. Cholinergic deficit, together with other underlying mechanisms, leads the to onset and progression of the disease.
Giovanni Ribaudo +2 more
doaj +1 more source
Phosphodiesterase Inhibitors [PDF]
International Cardiovascular Forum Journal, 2019 Phosphodiesterases (PDEs) comprise a superfamily with 11 subfamilies. Within these families, more than 40 isoforms are expressed. Phosphodiesterase-3 inhibitors (PDE3i) are used as inotrope/vasodilators for acute heart failure (HF), and PDE5i for pulmonary hypertension and erectile dysfunction.
Rui Plácido, Mitja Lainscak
openaire +2 more sources
Pulmonary Circulation, 2020 Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real-world adherence to different pulmonary arterial hypertension drug classes are limited.
Robert P. Frantz +6 more
doaj +1 more source
Pulmonary Circulation, 2020 Phosphodiesterase-5 inhibitors are commonly used in pulmonary arterial hypertension but, as suggested by the RESPITE study, phosphodiesterase-5 inhibitor therapy (mono-/combination) does not always have a satisfactory treatment effect.
Clara Hjalmarsson +8 more
doaj +1 more source
Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
Frontiers in Pharmacology, 2020 Allergic rhinitis/rhinosinusitis (AR) is the most common allergic disease. It affects patients’ quality of life and may influence the severity of lower airway disease such as asthma. Therefore, its treatment is of great importance.
Viera Janosova +5 more
doaj +1 more source
Nonsteroidal anti-inflammatory drugs as potential ecto-nucleotide phosphodiesterase inhibitors
Brazilian Journal of Pharmaceutical Sciences, 2020 Phosphodiesterases (PDE) are group of enzymes which catalyze the hydrolysis of cAMP and cGMP. Since these cyclic phosphate moieties worked as intracellular second messengers in numerous physiological processes, their inhibition can affect normal ...
Shumaila Tasneem +2 more
doaj +1 more source